Immucell (ICCC) Income towards Parent Company (2010 - 2026)
Immucell's (ICCC) quarterly Income towards Parent Company came in at -$2.8 million in Q4 2025, down 653.71% YoY from $514555.0 in Q4 2024, and down 1938.77% on a QoQ basis from -$139748.0 in Q3 2025.
Immucell (ICCC) Income towards Parent Company (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Income towards Parent Company data on file, last reported at -$2.8 million in Q4 2025.
- Quarterly Income towards Parent Company fell 653.71% year-over-year to -$2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.0 million (up 51.78% YoY) and the FY2025 annual result came in at -$1.0 million, up 51.78% from the prior year.
- Income towards Parent Company retreated to -$2.8 million in Q4 2025, from -$139748.0 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $1.4 million in Q1 2025 to a low of -$2.8 million in Q4 2025.
- A 5-year average of -$574401.8 and a median of -$548190.5 in 2021 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company sank 2275.18% — and 2025, when it soared 430.46%.
- Tracing ICCC's Income towards Parent Company over 5 years: stood at $74134.0 in 2021, then slumped by 2275.18% to -$1.6 million in 2022, then grew by 29.32% to -$1.1 million in 2023, then surged by 145.14% to $514555.0 in 2024, then plunged by 653.71% to -$2.8 million in 2025.
- The last three Income towards Parent Company figures came in at -$2.8 million (Q4 2025), -$139748.0 (Q3 2025), and $501880.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Dec 31, 2025 | -2.85 Mn |
| Sep 30, 2025 | -139,748.00 |
| Jun 30, 2025 | 501,880.00 |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | 514,555.00 |
| Sep 30, 2024 | -701,690.00 |
| Jun 30, 2024 | -1.53 Mn |
| Mar 31, 2024 | -437,868.00 |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | -940,000.00 |
| Jun 30, 2023 | -1.38 Mn |
| Mar 31, 2023 | -2.32 Mn |
| Dec 31, 2022 | -1.61 Mn |
| Sep 30, 2022 | -655,078.00 |
| Jun 30, 2022 | -684,148.00 |
| Mar 31, 2022 | 513,287.00 |
| Dec 31, 2021 | 74,134.00 |
| Sep 30, 2021 | 147,764.00 |
| Jun 30, 2021 | 141,113.00 |